[08] The present specification discloses solid solution pharmaceutical compositions. The pharmaceutical compositions disclosed herein are formulated in a manner that essentially produces a lipid-adjuvant delivery system that enables a therapeutic compound having an activity that modulates lipid and/or lipoprotein levels to be delivered in a manner that more effectively treats a cardiovascular disease.

SUMMARY

[09] Aspects of the present specification disclose, in part, a solid solution pharmaceutical composition comprising a therapeutic compound, one or more room temperature solid lipids. The solid solution pharmaceutical composition disclosed herein may further comprise one or more room temperature liquid lipids, one or more stabilizing agents, one or more neutralizing agents, or any combination thereof. A therapeutic compound may have an activity that normalizes lipid levels.

[09a] In one aspect, there is provided a solution pharmaceutical composition comprising:

a) one or more statins in an amount of about 1% to about 30% by weight of the pharmaceutical composition;

b) one or more pharmaceutically-acceptable hard fats in an amount of about 30% to about 75% by weight of the pharmaceutical composition;

c) one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides that is liquid at room temperature in an amount of about 8% to about 40% by weight of the pharmaceutical composition,

wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower.

[09b] In one aspect, there is provided of a pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a cardiovascular disease

[010] Other aspects of the present specification disclose, in part, a method of preparing a solid solution pharmaceutical composition disclosed herein. A method disclosed herein comprises the steps of a) contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids under conditions which allow the therapeutic compound to dissolve in the lipids; and b) contacting the compound/lipid solution with one or more room temperature solid lipids under conditions which allow the formation of a solid solution composition. In aspects of this method, heat is applied to dissolve the therapeutic compound into the one or more room temperature liquid lipids to create a solution. In other aspects of this method, step (a) comprises contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids and/or one or more stabilizing agents, and/or one or more neutralizing agents under conditions which allow the therapeutic compound to dissolve in the lipids.

[011] Other aspects of the present specification disclose a method of treating an individual with a cardiovascular disease, the method comprising the step of administering to the individual in need thereof a solid solution pharmaceutical composition disclosed herein, wherein administration results in a reduction in a symptom associated with the cardiovascular disease, thereby treating the individual.

[012] Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a cardiovascular disease.

[013] Other aspects of the present specification disclose a solid solution pharmaceutical composition disclosed herein for use in the treatment of a cardiovascular disease.

[014] Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein for the treatment of a cardiovascular disease.

BREIF DESCRIPTION OF THE DRAWINGS